Abstract
Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Current Alzheimer Research
Title:Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease
Volume: 15 Issue: 8
Author(s): Cassandra Morrison*, Sheida Rabipour, Frank Knoefel, Christine Sheppard and Vanessa Taler
Affiliation:
- School of Psychology, University of Ottawa, Ottawa, ON, Canada, Bruyère Research Institute, Ottawa, ON,Canada
Keywords: Alzheimer's disease, event-related potentials, mild cognitive impairment, P50, N100, P100, N200, P300.
Abstract: Background: Mild cognitive deficits are more likely to occur with increasing age, and become more pronounced for people diagnosed with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Conventional methods to identify cognitive declines (i.e., neuropsychological testing and clinical judgment) can lead to false positive diagnoses of cognitive impairment. Tools such as electroencephalography (EEG) offer additional measures of cognitive processing, indexing the electrophysiological changes associated with aging, MCI and AD.
Objective: We reviewed the literature on EEG to determine if auditory event-related potentials (ERPs) could distinguish between healthy aging, MCI, and AD.
Method: We searched two electronic databases (Medline and PyscInfo) for articles published between January 2005 and April 2017. Articles were considered for review if they included: i) participants 60 years of age or older; ii) healthy older adults or those diagnosed with MCI or AD; iii) at least one auditory elicited ERP component.
Results: Our search revealed 1532 articles (800 after removing duplicates); 719 were excluded through title/abstract review, and of the 81 remaining articles, 30 satisfied inclusion criteria. All studies compared cognitive function between at least two of the three selected populations. Our findings suggest that the P300 and N200 components may distinguish between healthy cognitive aging, MCI, and AD.
Conclusion: ERPs may be sensitive to progressive cognitive changes due to MCI and AD. The P300 and N200 may help identify patients who are likely to progress from MCI to AD, and could be a valuable clinical tool.
Export Options
About this article
Cite this article as:
Morrison Cassandra*, Rabipour Sheida , Knoefel Frank , Sheppard Christine and Taler Vanessa , Auditory Event-related Potentials in Mild Cognitive Impairment and Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (8) . https://dx.doi.org/10.2174/1567205015666180123123209
DOI https://dx.doi.org/10.2174/1567205015666180123123209 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Regional Editor:
Current Drug Discovery Technologies P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology On the Involvement of H2S in Nitroso Signaling and Other Mechanisms of H2S Action
Current Pharmaceutical Biotechnology Natural Compounds Therapeutic Features in Brain Disorders by Experimental, Bioinformatics and Cheminformatics Methods
Current Medicinal Chemistry Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Current Pharmaceutical Design A Review on the Phytochemicals, Ethnomedicine Uses and Pharmacology of Ficus Species
Current Traditional Medicine HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Mind-Body Practices and the Adolescent Brain: Clinical Neuroimaging Studies
Adolescent Psychiatry Exploiting High-Throughput Ion Channel Screening Technologies in Integrated Drug Discovery
Current Pharmaceutical Design Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Recent Inventions on Receptor Tyrosine Kinase RET Modulation
Recent Patents on Biotechnology Flavonoids as Natural Inhibitors of Jack Bean Urease Enzyme
Letters in Drug Design & Discovery Opioid Receptor Ligands Derived from Food Proteins
Current Pharmaceutical Design Ivabradine: The Hope for a Good Treatment of Ischemic Heart Disease
Current Medicinal Chemistry Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets In Silico Validation and Structure Activity Relationship Study of a Series of Pyridine-3-carbohydrazide Derivatives as Potential Anticonvulsants in Generalized and Partial Seizures
Central Nervous System Agents in Medicinal Chemistry Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy
Current Neuropharmacology Valproic acid, A Potential Inducer of Osteogenesis in Mouse Mesenchymal Stem Cells
Current Molecular Pharmacology Polyphenols and Neuroprotection against Ischemia and Neurodegeneration
Mini-Reviews in Medicinal Chemistry